Telix Reports Third Quarter 2026 Financial Performance

Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, driven by strong demand for PSMA imaging products Gozellix and Illuccix. The company received FDA approval for Pixclara for glioma imaging and announced a transformational merger with Isotope Technologies Munich (ITM) for US$1.65 billion upfront, creating a vertically integrated radiopharmaceutical company with expanded isotope production capabilities. Telix reaffirmed FY 2026 revenue guidance exceeding US$1 billion.